The P/E of -1.22 is arithmetically meaningless given negative trailing earnings, but the P/B of 0.98 is analytically revealing: investors are pricing the equity at roughly par to book, which includes $39.2M in goodwill that has sat static for ten consecutive quarters. For a pre-commercial gene therapy company, a sub-1.0 P/B implies the market is discounting the entire intangible pipeline as having near-zero recoverable value in a downside scenario, rather than assigning it option value as typically seen in earlier-stage peers like CRSP at 2.41x book. This warrants monitoring: any clinical catalyst would need to materially reset the market's implied franchise valuation, while a goodwill impairment could push reported book value — and the P/B ratio — lower still.

The ROIC trajectory shows a clear erosion from the -11.3% level seen in early 2024 to the -18.4% posted in 2026Q2, suggesting that despite SG&A reductions, the ratio of operating losses to invested capital has worsened — the company is destroying more capital per dollar deployed. The ROE spike to +40.6% in 2026Q2 appears to be entirely an artifact of the approximately $170M non-operating gain and should be disregarded as a measure of earning power. True economic return on capital remains deeply negative, and the trend suggests the compounding equation will only turn positive once clinical programs convert to revenue.

Total debt of approximately $25M against equity of $400M+ represents a leverage profile that is essentially undeployed — the D/E of 0.07 in 2026Q2 leaves substantial headroom if management chooses to access credit markets rather than issue equity. The interest coverage ratio of 279.7x in 2026Q2 is an artifact of the non-recurring gain and should be normalized against the historical pattern of negative coverage (ranging from -11.9x to -146.9x), which reflects the fact that RCKT has been servicing interest from its balance sheet rather than from operating income. Investors should note that while debt service is currently trivially manageable, future financing capacity may be constrained by market conditions for pre-commercial gene therapy companies.

The sharp liquidity improvement masks an underlying pattern of cash depletion: total assets fell from $527.7M at end-2024Q4 to $285.4M at 2026Q1 before rebounding to $423.1M, suggesting the 2026Q2 balance sheet strength may not be self-sustaining absent additional financing or partnership inflows. With cash burn averaging roughly $48M per quarter over the last ten periods, the current cash position implies a runway of approximately 10-12 quarters under current operating patterns — comfortable in absolute terms but insufficient to fund a Phase 3 program without external capital. The quick ratio being identical to the current ratio (9.24x) reflects the fact that virtually all current assets are cash and equivalents, leaving no inventory dependency.

The peer comparison reveals RCKT's ROIC of -18.4% (2026Q2) sits between CRSP (-22.3%) and BEAM (-31.1%), placing it in the middle of the gene therapy cohort on capital destruction intensity. Notably, RCKT's D/E of 0.07 is among the lowest in the peer group — below CRSP (0.21), NTLA (0.14), and dramatically below EDIT (2.81) — suggesting a more conservative balance sheet posture that may provide greater resilience in a prolonged funding drought. However, the P/B of 0.98 is the lowest in the peer set, implying the market is assigning less franchise value per dollar of book to RCKT than to any comparable — a discount that appears disproportionate to RCKT's relatively better ROE trajectory and warrants further investigation.